Ambalal Sarabhai ENT L

NSE: AMBALALSA · Pharmaceuticals · sector

₹35.56NSE close 2026-10-26

Key numbers

Market cap₹273 cr

Price₹35.56

52w high / low₹50 / ₹30

P/E19.3xSector median 27.9x

P/B1.7xSector median 2.9x

Book value₹20.7

Dividend yield–Sector median 0.48%

ROE8.7%Sector median 11.7%

ROCE8.8%Sector median 12.3%

OPM6.8%Sector median 14.0%

Debt / equity0.33xSector median 0.16x

EV/EBITDA21.8xSector median 18.6x

Interest cover4.5x

Current ratio1.27x

Sales growth 3y+279.2%Sector median +9.6%

Profit growth 3y+63.0%Sector median +13.3%

PEG0.31x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹19 cr vs borrowings ₹52 cr (FY26): borrowings are higher by ₹32 cr.
Operating profit covered interest 4.5x in the last 12 months.
Net loss in 2 of the last 6 quarters.
Other income was 68% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹35.56 on 2026-10-26: -28.9% from the 52-week high, +17.9% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹65.57 · low ₹24.28

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	65	40	44	52	65	44
EBITDA	-2	1	1	3	6	5
OPM %	-2.5%	3.7%	1.1%	6.3%	8.7%	10.4%
Other income	2	8	2	3	3	2
Net profit	-0	8	-1	3	6	4
EPS (₹)	0.04	1.07	0.07	0.40	0.85	0.52
Revenue YoY					+1.0%	+8.0%
Profit YoY					–	-51.6%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	0	4	4	196	202	206
EBITDA	-36	-6	-7	1	11	14
Net profit	3	4	3	5	18	13
EPS (₹)	0.39	0.54	0.34	0.64	2.32	1.84
Revenue growth		+2,753.8%	+2.7%	+5,049.3%	+3.1%	–
Profit growth		+38.9%	-37.2%	+91.1%	+261.1%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+279.2%	–	–
Net profit	+63.0%	–	–
EPS	+62.6%	–	–
Share price	–	– (2y)	–

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	140	158
Borrowings	49	52
Cash & equivalents	12	19
Total assets	270	281
Fixed assets	63	60
Capital work in progress	0	2
Investments	32	1
Receivables	44	48
Inventory	24	22
Payables	50	41

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-18	13
Cash from investing	13	-10
Cash from financing	-2	-2
Capex	3	6
Free cash flow	-20	7

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	3.5%	11.2%
ROCE %	4.5%	10.6%
Debtor days	82	86
Inventory days	75	68
Payable days	158	125
Cash conversion cycle (days)	-1	29
Working capital days	-4	48

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
AMBALALSA	₹273 cr	19.3x	1.7x	8.7%	8.8%	6.8%	+279.2%	–

All 185 companies in Pharmaceuticals →

Business segments (2026-06-30)

Segment	Revenue	Share	EBIT	Margin
Pharmaceuticals	₹25 cr	58.0%	₹4 cr	17.4%
Electronics	₹18 cr	42.0%	₹1 cr	6.9%

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	AMBALALSA
BSE code	500009
ISIN	INE432A01017
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.